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ABSTRACT
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in 
the Western world, whereas in Asia the incidence is about 10 times lower. The basis 
for this ethnic and geographic variation is currently unknown. The aim of this study 
was to characterize IGHVDJ rearrangements and stereotype of the HCDR3 region in a 
series of 623 Chinese CLL, in order to identify possible differences in immunoglobulin 
gene usage and their potential pathogenetic implications. Chinese CLL were compared 
to 789 Italian CLL. Chinese patients showed a higher proportion of mutated IGHV 
and a more frequent usage of IGHV3-7, IGHV3-74, IGHV4-39 and IGHV4-59 genes. A 
significantly lower usage of IGHV1-69 and IGHV1-2 was documented, with comparable 
IGHV3-21 frequency (3% Chinese vs 3.8% Italian CLL). The proportion of known 
stereotyped receptors was significantly lower in Chinese (19.7%) than in Italian CLL 
(25.8%), despite a significantly higher frequency of subset #8 (p= 0.0001). Moreover, 
new paired clusters were identified among Chinese cases. Overall, these data support 
a potential different antigenic exposure between Eastern and Western CLL.
INTRODUCTION
Chronic lymphocytic leukemia (CLL) is 
characterized by a variable clinical course, driven by the 
immunogenetic and molecular heterogeneity of the disease 
[1-5].
The heterogeneity of CLL is also reflected by the 
different incidence in populations with diverse ethnic 
and geographic distribution. CLL is the most common 
leukemia among adults in the Western hemisphere (~30% 
of all leukemias), but is rare in Asian countries [6, 7]. The 
age-adjusted incidence rate (AAIR) is about 4.4 new cases 
x 100.000 individuals/year in the US (2007-2011) [8]. In 
contrast, the AAIR in Asians is about 10 times lower, with 
0.2-0.3 new cases x 100.000 individuals/year [8, 9]. The 
reasons for this epidemiologic heterogeneity remain to 
be defined. The risk of developing CLL does not change 
among Asians residing in the US and in their descendants 
[10, 11]. Therefore, the genetic background is important 
in determining the risk of the disease, beyond potential 
environmental factors.
There are some data on the clinico-biologic features 
of Asian CLL [12-14]. The prognostic impact of CD38 
[15], ZAP-70 [16], genetic lesions evaluated by FISH [17, 
18] and of other biologic markers such as CLLU1 [19], 
lipoprotein lipase [20], serum thymidine-kinase [21] seems 
confirmed also in Asians CLL. On the contrary, a different 
clinical presentation, a younger age at diagnosis and a 
worse prognosis have been reported [22]. Furthermore, 
some differences between Chinese and European CLL in 
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the incidence and prognostic impact of mutations in driver 
genes (SF3B1, NOTCH1, MYD88, BIRC3, TP53) have 
been suggested [23].
To date, little is known on the IGHV gene 
representation and mutations in Asian compared to 
Caucasian CLL. Indeed, some differences have so far 
been reported only in small cohorts of patients [24-
27]. The B-cell receptor (BCR) repertoire in CLL is 
influenced by the genetic susceptibility and/or by the 
existence of a promoting pressure derived from different 
antigenic elements. The potential role of antigens in the 
pathogenesis of CLL is further supported by the presence 
of the non-stochastic pairing of IGHV, IGKV and IGLV 
genes, which leads to nearly identical BCR sequences 
of heavy chain complementarity determining region 3 
(HCDR3) region, described as “stereotyped” BCR, in 
about 30% of Caucasian CLL [28].
In this study, we investigated IGHV gene usage, 
mutational status and HCDR3 in the largest series of 
Chinese CLL so far reported, and compared them to those 
present in Italian CLL. Despite general analogous features, 
Chinese and Italian CLL showed significant differences 
in IGHVDJ gene usage, mutations and stereotypy. These 
findings raise the hypothesis that diverse specific antigens 
are implicated in the pathogenesis of Asian CLL.
RESULTS
Italian CLL: IGHV gene usage, mutation 
analysis and HCDR3 features
A total of 792 IGHVDJ productive rearrangements 
from 789 Italian CLL cases were evaluated; 2 cases carried 
double and triple in-frame rearrangements, respectively. 
Using the 2% cut-off to discriminate between mutated 
and unmutated rearrangements, 387 (49%) of the 792 
sequences analyzed had more than 2% difference from the 
most similar germline gene and were classified as mutated 
with a median of 7.4% (range 2-17%) mutations/case The 
remaining 405 (51%) were considered as unmutated, of 
which 278 (68%) displayed a 100% sequence identity 
to the corresponding germline IGHV gene sequences 
(Supplementary Table S1A). The IGHVDJ subgroup and 
gene usage were for the most part comparable to those 
reported in previous studies [28-31], showing no relevant 
differences in the frequency of the most representative 
genes. As expected, the analysis revealed that the most 
common IGHV subgroup was IGHV3 (364; 46.0%), 
followed by IGHV1 (199; 25.1%) and IGHV4 (163; 20.6 
%) (Supplementary Table S1B).
When we examined the IGHV genes, the most 
frequently encountered were IGHV1-69 (110; 13.9%), 
IGHV4-34 (77; 9.7%), IGHV3-23 (51; 6.4%), IGHV3-30 
(46; 5.8%), IGHV1-2 (44; 5.6%), IGHV3-7 (42; 5.3%), 
IGHV3-11 (31; 3.9%), IGHV3-21 (30; 3.8%), IGHV3-
48 (28; 3.5%), IGHV4-39 (27; 3.4%), IGHV3-33 (27; 
3.4%); collectively, these genes accounted for 65% of 
the cases, in line with the reported features of Caucasian 
CLL (Supplementary Table S1B). In our cohort, we also 
confirmed the known low frequency of the IGHV3-21 
gene in CLL patients of Mediterranean origin, with one 
third of cases being mutated [29].
As expected, the IGVH1-69 gene was over-
represented in the unmutated group (p=0.0001), whilst 
IGHV4-34 (p=0.0001), IGHV3-7 (p=0.0001) and IGHV3-
23 (p=0.0001) were over-represented in the mutated 
group.
Among the 792 sequences, IGHD genes were 
identified in 774 cases and IGHD3 was the most 
frequently represented (337; 43.5%) followed by IGHD2 
(135; 17.4%) and IGHD6 (107; 13.8%). The IGHD3-
3 (133; 17.2%) gene was the most frequently used 
followed by IGHD3-22 (82; 10.6%) (Supplementary 
Table S1C).
With regard to the IGHJ gene usage, the most 
frequent subgroup was IGHJ4 (332; 41.9%), followed 
by IGHJ6 (264; 33.3%) and IGHJ5 (89; 11.2%) 
(Supplementary Table S1D). Moreover, IGHJ4 recurred 
in mutated sequences (p= 0.0001), whilst IGHJ6 was 
recurrent in unmutated rearrangements (p= 0.0001).
We also confirmed the presence of specific IGHV, 
IGHD and IGHJ gene combinations, in particular, for 
the IGHV1-69 gene the strongly biased association with 
IGHD3-3 (32/110; 29%) (p= 0.0005) and IGHJ6 (63/110; 
57%) segments (p= 0.0001).
The median length of HCDR3 was 19 amino acids 
(range, 7-35). Unmutated sequences had significantly 
longer HCDR3s than mutated sequences: median length 
22 versus 17 amino acids (p= 0.0001).
Cluster analysis of the HCDR3 region allowed to 
recognize 204 of 792 cases (25.8%) with stereotyped 
BCRs (Supplementary Table S1E-S1F) belonging to 72 
different subsets. We confirmed a significantly higher 
frequency of unmutated (153/405; 37.7%) than mutated 
(51/387; 13.2%) stereotyped sequences (p= 0.0001). Of 
the major stereotyped subsets of Caucasian CLL, the 
most frequent in the present Italian series were subset #1 
(20.9%), #4 (11.3%) and #2 (10.4%).
The most represented IGHV genes in stereotyped 
HCDR3 were: IGHV1-69 (#3, #5, #6, #7), IGHV4-34 (#4) 
and IGHV3-21 (#2).
Moreover, we identified 10 (4.9%) sequences that 
fell into 5 groups with identical HCDR3 and thus were 
defined as paired clusters.
Chinese CLL: IGHV gene usage, mutation 
analysis and HCDR3 features
A total of 631 productive IGHVDJ rearrangements 
were sequenced from the cohort of 623 Chinese CLL 
patients; 8 (1.3%) cases showed biallelic IGHVDJ 
rearrangements. A total of 415 of the 631 sequences 
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analyzed (66%) were defined as mutated, with a median 
of 7% (range 2-22%) mutations/case, whereas 216 (34%) 
sequences had unmutated IGHV genes, with 121 (56%) in 
100% germline configuration (Supplementary Table S2A).
Analysis of the IGHV subgroups showed a higher 
usage of IGHV3 (295; 46.8%) followed by IGHV4 (181; 
28.7%) and IGHV1 (98; 15.5%) (Supplementary Table 
S2B). The most frequent IGHV genes were IGHV4-34 
(70; 11.1%), IGHV3-23 (53; 8.4%), IGHV3-7 (51; 8.1%), 
IGHV4-39 (43; 6.8%), IGHV1-69 (36; 5.7%), IGHV4-59 
(30; 4.8%), IGHV3-30 (27; 4.3%), IGHV3-74 (23; 3.7%), 
IGHV1-3 (23; 3.7%) and IGHV3-48 (22; 3.5%). Overall, 
these genes were found in 60% of the analyzed cases. 
Cumulative results are summarized in Supplementary 
Table S2B. The known biased usage was found, with 
IGVH1-69 (p= 0.0001) gene over-represented in the 
unmutated group, and IGHV4-34 (p= 0.0001) and IGHV3-
7 (p= 0.003) in the mutated group. IGHV3-21 represented 
the eleventh group in frequency (19; 3%), with two thirds 
being mutated (mutated, n=13; unmutated, n=6).
IGHD genes were identified in 622 of 631 
productive rearrangements. Overall, the most frequently 
used subgroup was IGHD3 (239; 38.4%), followed 
by IGHD6 (122; 19.6%) and IGHD2 (91; 14.6%) 
(Supplementary Table S2C). The most prevalent IGHD 
genes were IGHD3-10 (74; 11.9%) and IGHD3-22 (59; 
9.5%).
Regarding IGHJ gene usage, among Chinese 
patients there was an over-representation of the 
IGHJ4 (289; 45.8%) and IGHJ6 (161; 25.5%) genes 
(Supplementary Table S2D). In addition, IGHJ4 recurred 
in mutated rearrangements (p= 0.0001), whilst IGHJ6 
was recurrent in unmutated rearrangements (p= 0.0028). 
Focusing on IGHVDJ rearrangements, we identified a 
biased association of IGHV1-69 with IGHD3-3 and JH6 
gene, similarly to Caucasian CLL, although a significant 
correlation was observed only with IGHJ6 (p=0.016).
The HCDR3 median length was 17 amino acids 
(range, 7-35). Significantly longer HCDR3s were observed 
in unmutated versus mutated sequences (median lengths, 
21 versus 16 amino acids; p= 0.0001). The frequency of 
a stereotyped HCDR3 was significantly higher among 
unmutated (72/216; 33.3%) than mutated (52/415; 12.5%) 
sequences (p= 0.0001). We identified 124 stereotyped 
HCDR3 out of 631 cases (19.7%), belonging to 48 
different subsets, of which 16 (12.9%) have not been 
reported previously and were named as novel clusters 
(see below). The major stereotyped subsets of Caucasian 
CLL collectively represent a substantial proportion of 
stereotyped sequences also in the Chinese series, with a 
preferential recurrence of subset #8 (27.3%), #1 (21.2%), 
#4 (16.7%), while the subset #2 (1.5%) appeared to be less 
represented (Supplementary Table S2E).
By comparing the IGHV usage of stereotyped 
sequences with those not belonging to any cluster, the 
IGHV1 (p= 0.03) and IGHV4 (p= 0.0004) subgroups were 
the most frequently utilized in stereotyped sequences, 
whereas IGVH3 was preferentially employed by non-
homologous sequences (p= 0.0001). Indeed, the most 
frequent stereotyped IGHV genes were: IGHV4-34 (#4) 
IGHV4-39 (#8) and finally IGHV1-69 (#3, #5, #6, #7).
Regarding the 16 novel clusters (corresponding to 
33 sequences), two were potential new subsets (composed 
of 3 Chinese CLL and 2 Chinese plus 2 Italian CLL, 
respectively) and 14 were paired clusters (all Chinese), 
as shown in Supplementary Table S2F. In contrast to 
common subsets, the majority of novel clusters were 
mutated (19/33 sequences; 57.5%). Of interest, 15 of 
19 novel mutated sequences expressed genes from the 
IGHV3 subgroup, of which IGHV3-23 (8/33; 24.2%) was 
the most represented gene.
Comparison between Italian and Chinese CLL 
reveals differences in IGHV mutational status 
and gene repertoire
Comparing the two series, Chinese CLL showed 
a higher proportion of cases with mutated IGHV than 
Italian CLL. Such difference appeared to be statistically 
significant - mutated IGHV 66% and unmutated IGHV 
34% vs mutated IGHV 49% and unmutated IGHV 51%, 
respectively (p= 0.0001) - and remained significant also 
after exclusion of pre-treated cases (p= 0.0001).
Whilst the IGHV3 subgroup was predominantly 
expressed both in Chinese and Italian patients, there was 
an inversion between IGHV1 and IGHV4 frequency. In 
fact, the frequency of IGVH1 in Chinese CLL resulted 
lower (p= 0.0001), while the IGHV4 subgroup was 
significantly higher (p= 0.0004) (Figure 1A).
In line with these results, the IGHV gene usage 
highlighted differences in the 10 most frequent genes of 
Italian and Chinese CLL. Overall, the 10 most frequent 
IGHV genes employed by Italian CLL represented 50% 
of the IGHV genes used by the Chinese CLL, showing 
a significant difference (p= 0.0001). In fact, IGHV1-69 
(p= 0.0001) and IGHV1-2 (p= 0.0002) were significantly 
under-represented in Chinese CLL, whilst IGHV3-7 (p= 
0.04) and IGHV4-39 (p= 0.004) were more recurrent 
among Chinese than Italian patients. In addition, the 
IGHV4-59 (p= 0.01), IGHV1-3 (p= 0.02) and IGHV3-
74 (p= 0.04) genes were most typically used by Chinese 
CLL (12%) but not by the Italian cohort of CLL (5%) (p= 
0.0001). IGHV3-21 showed a comparable frequency (3% 
Chinese vs 3.8% Italian CLL) (Figure 1B).
The known pattern of mutations for each IGHV gene 
was largely conserved in both Chinese and Italian CLL. 
In fact, the IGHV1-69 gene carried few or no mutations, 
while IGHV4-34, IGHV3-7 and IGHV3-23 showed a high 
frequency of mutations in both cohorts. Contrariwise, 
IGHV3-21 (p= 0.002) and IGHV1-2 (p= 0.03) genes 
showed a higher frequency of mutations among Chinese 
than Italian CLL (Figure 2). In particular, IGHV3-21 
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showed a median of 9.4% (range 2.5-18.9%) mutations in 
Chinese CLL vs 4% (range 2.5-9%) in Italian CLL.
Also the comparison of IGHD subgroups and genes 
allowed to identify additional differences between the 
two CLL cohorts. The IGHD6 subgroup, the second most 
frequent after the IGHD3 family in Chinese CLL, was 
significantly increased compared to Italian CLL (p= 0.004). 
Similarly, there was a significant over-usage of IGHD3-10 
(p= 0.002), IGHD6-13 (p= 0.0001) and IGHD2-21 (p= 
0.03) genes and under-usage of IGHD3-3 (p= 0.0001) and 
IGHD2-2 (p= 0.02) genes in Chinese CLL.
As for the IGHJ subgroup, although the distribution 
was similar among the two populations, IGHJ6 (p= 0.002) 
was significantly under-represented in the Chinese series.
Comparative analysis of the HCDR3 sequences 
revealed notable differences. The proportion of known 
stereotyped receptors was significantly lower in Chinese 
(19.7%) than in Italian CLL (25.8%) (p= 0.007) 
(Figure 3A). In particular, within the major subsets, a 
significantly higher frequency of subset #8 (p= 0.0001) 
and lower frequency of subset #2 (p= 0.03) were observed 
in the Chinese cohort (Figure 3B). These features are 
due to the different frequencies of the stereotyped genes, 
given that most IGHV genes showed the same propensity 
to be used in stereotyped rearrangements in both series 
(Figure 4). In fact, the most represented stereotyped 
genes in Italian CLL were IGHV1-69> IGHV4-34> 
IGHV1-2> IGHV3-21> IGHV3-30> IGHV4-39, whilst 
being IGHV4-34> IGHV4-39> IGHV1-69> IGHV1-3> 
IGHV3-23> IGHV4-59 in Chinese CLL. In particular, 
the stereotyped HCDR3 sequences expressing IGHV1-69 
and IGHV3-21 genes were significantly less represented in 
Chinese CLL than Italian CLL (p= 0.0006 and p= 0.0003, 
respectively); indeed, the IGHV3-21 gene exhibited 
a higher heterogeneity within its HCDR3 sequence in 
Chinese than Italian CLL (Figure 4).
Figure 1: Comparison between Chinese and Italian CLL. A. Frequency of the IGHV subgroups. B. Frequency of the IGHV 
genes. * marks the significant differences (p values in the text). Data are represented as percentage.
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Clinical impact of IGHV features in Chinese 
CLL
Prognosis was evaluated on 612 Chinese CLL patients, 
with a median follow-up of 28 months (range: 0-270.9). The 
median overall survival (OS) was 121.7 months for 566 
evaluable cases. Treatment-free interval (TFI) from diagnosis 
was 18.4 months (range: 0-194.8) for 580 evaluable cases, 
327 of whom required treatment. Richter’s transformation 
occurred in 16 of 575 evaluable cases (2.8%).
CLL in Binet stages A, B or C had a median OS of 
165.1, 98 and 82.2 months, respectively (p= 0.0001).
Chinese CLL with unmutated IGHV showed a 
poor prognosis in terms of OS (85.1 vs 165.1 months, 
p<0.0001) and TFI (4.0 vs 46.1 months, p<0.0001) 
compared to mutated IGHV cases, as expected.
As reported for Caucasian CLL, subset #1 Chinese 
CLL (n=14) showed a poor prognosis in terms of OS 
(median OS 28.0 months vs 85.1 for unmutated IGHV 
vs 165.1 for mutated IGHV, p<0.0001) and TFI (median 
TFI 0.8 months vs 4.8 for unmutated IGHV vs 46.2 for 
mutated IGHV, p<0.0001), even worse than that of the 
other IGHV unmutated CLL.
Subset #8 CLL (n=18) showed an OS (median 82.2 
months) and TFI (median 1.7 months) as poor as the other 
IGHV unmutated CLL, although there was a significant 
association with the occurrence of Richter’s syndrome (n=3 
out of 16) (p= 0.0095), as reported for Caucasian CLL.
Figure 2: Mutational Patterns of IGHV genes. A. Chinese CLL. B. Italian CLL. Data are represented as percentage.
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The low number of events did not allow to analyze 
the prognostic impact of subset #4 (n=11).
Finally, the OS and TFI of Chinese patients with 
IGVH3-23 were not different from the other cases with 
mutated IGHV (p= 0.48 and p= 0.41, respectively). 
The low number of events did not allow to highlight a 
different outcome between stereotyped IGHV3-23 (n=7) 
and heterogeneous IGHV3-23 (n=32) cases.
DISCUSSION
In Caucasian CLL, the extensive research on 
IGHVDJ rearrangements has shown that immunoglobulin 
gene usage is not random, but biased by the recurrence 
of certain IGHV genes as well as by the existence of 
subsets with stereotyped BCR [31, 32]. In contrast, little 
is known about the IGHV features of Asian CLL, although 
some differences have been reported in small cohorts of 
Chinese and Japanese patients [24, 25]. In order to define 
geographic and ethnic immunoglobulin gene variations, 
we characterized IGHVDJ rearrangements and HCDR3 
stereotypy in a large series of Chinese CLL and compared 
them with Italian CLL. Our Italian cohort is representative 
of Caucasian CLL, being comparable with other Italian 
[30] and Western series [28].
A mutated IGHV status was more frequent in 
Chinese than in Italian CLL, thus consolidating previous 
observations made in small Asian series [24, 25]. This 
holds true also when considering patients in homogeneous 
phases of disease.
With regard to the IGHV subgroups, Chinese CLL 
showed an IGHV3>IGHV4>IGHV1 order of frequency, 
significantly different from Italian CLL patients, who 
showed an IGHV3>IGHV1>IGHV4 distribution. These 
Figure 3: Stereotyped BCRs representation. A. Chinese and Italian stereotyped and non-stereotyped BCRs. B. Frequency of Major 
subsets in Chinese and Italian series. * marks the significant differences (p values in the text). Data are represented as percentage.
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results support those reported on both Chinese [24] and 
Japanese [25, 33] CLL, confirming that this family usage 
is typical of Asian CLL.
Focusing on the IGHV gene distribution, 
also Chinese CLL showed a non-random use of 
immunoglobulin genes, with the IGHV4-34 being the 
most represented. Moreover, IGHV1-69 and IGHV1-
2 were significantly under-represented in Chinese CLL, 
whilst IGHV4-39 and IGHV3-7 were more recurrent in 
Chinese than Italian CLL. Furthermore, the IGHV4-59, 
IGHV3-74 and IGHV1-3 genes were common in Chinese 
CLL, whilst rare in Italian CLL.
The known pattern of mutations for each specific 
IGHV gene was largely conserved, i.e. the IGHV1-69 gene 
shows analogous molecular features in Caucasian and in 
Chinese CLL, being unmutated and representing the most 
frequent gene of the IGHV1 subgroup [28, 34]. Thus, the low 
recurrence of the IGHV1-69 gene in Chinese CLL largely 
accounts for the lower overall frequency of the IGHV1 
subgroup and of unmutated cases. On the other hand, the 
high incidence of the IGHV3-7, IGHV4-39 and IGHV3-
74 genes could be responsible of the high representation 
of mutated IGHV, since these genes often show a mutated 
profile. Relevant exceptions are represented by the IGHV1-2 
gene, that was significantly more mutated in Chinese than 
in Italian CLL, and the IGHV3-21 gene. The latter, equally 
represented in Chinese (3%) and Italian CLL (3.8%), was 
more frequently mutated in China.
Our results reinforce those reported in other 
small Asian CLL series [24, 25], especially with regard 
to IGHV1-69 and IGHV3-7, strongly supporting the 
contribution of ethnic and geographic parameters in 
shaping the IGHV repertoire. Moreover, the same pattern 
is also reported in Iranian CLL [27], suggesting that this 
geographic-related variation is already established in the 
Middle-East. Thus, this different pattern between Eastern 
and Western CLL adds to the other known geographic 
variation related to the IGHV3-21 gene, over-represented 
in Northern European CLL compared to Mediterranean 
CLL [29].
We also identified additional differences in the 
frequencies of IGHD and IGHJ genes. Among others, a 
Figure 4. Frequency of stereotyped and heterogeneous BCRs for selected IGHV genes. A. Chinese CLL. B. Italian CLL. 
Data are represented as percentage.
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significant under-usage of IGHD3-3 and IGHJ6 genes 
was observed in the Chinese cohort. Given the specific 
combination of IGHV1-69 with the IGHD3-3 and IGHJ6 
genes in Caucasian CLL [28, 34], their low occurrence 
in Chinese CLL could be related to the low frequency of 
IGHV1-69. To our knowledge, these results have never 
been previously reported.
The analysis of HCDR3 sequences proved the 
presence of stereotyped BCR in one-third of Caucasian 
CLL [28, 30, 31], suggesting the recognition of a common 
antigenic determinant [35]. We therefore characterized the 
HCDR3 sequences in Chinese CLL, which have not been 
investigated so far, for their potentially relevant pathogenetic 
implications. Chinese CLL showed a significantly lower 
representation of stereotyped sequences (19.7%) compared to 
Italian CLL (25.8%). The stereotyped subsets defined major 
among Caucasian CLL collectively were over-represented 
also in the Chinese cohort, but with a significantly higher 
frequency of subset #8 (China vs Italy: 27.3% vs 4.3%) 
and a lower frequency of subset #2 (China vs Italy: 1.5% vs 
10.4%). Subset #8, the most represented Chinese stereotype, 
is characterized by the use of the IGHV4-39 gene, which 
is indeed one of the most recurrent gene in Chinese CLL. 
On the contrary, the low frequency of subset #2 is due to 
the heterogeneous HCDR3 of IGHV3-21 in Chinese CLL, 
whilst in Caucasian CLL the IGHV3-21 gene is mostly 
stereotyped [29]. The low frequency of subset #2 in Chinese 
CLL could parallel the recently reported low incidence of 
SF3B1 mutations [23], in line with their reported association 
in Caucasian CLL [36]. Of note, the clinical impact of 
CLL stereotypy is independent of the ethnic context, since 
in Chinese CLL subset #1 displayed a poor prognosis and 
subset #8 was related to an increased risk of transformation 
into Richter syndrome, similarly to Caucasian CLL [37, 38].
With the exception of the IGHV3-21 gene, it is 
worth noting that all the other IGHV genes (i.e. IGHV1-
69, IGHV4-39, etc) maintain the same proportion of 
homologous/heterologous BCR both in Chinese and in 
Italian CLL. Thus, the determinant of the lower frequency 
of stereotyped BCR in Chinese CLL could be due to the 
prevalence of certain genes (i.e. IGHV3-7 and IGHV3-74) 
and the reduced frequency of others (i.e. IGHV1-69), each 
maintaining the same tendency to stereotypy.
By clustering analysis, we detected 16 new 
paired clusters among Chinese cases, characterized 
by the remarkable recurrence of the IGHV3-23 gene; 
contrariwise, in Caucasian CLL this gene constantly 
exhibits an heterogeneous HCDR3 [39]. Moreover, 
IGHV3-23 gene usage is considered an independent 
negative prognosticator within Caucasian mutated CLL 
[39], but this was not the case among Chinese CLL.
In line with the proposal of Ghia et al. for Caucasian 
CLL [29], also in Chinese CLL the IGHV pattern may 
be due to either a specific genetic background and/or 
to the effects of potential environmental variables. The 
observation of new paired clusters in Chinese CLL, never 
reported in Caucasian CLL, supports the hypothesis of 
an Asian-specific antigenic selection at least in some 
cases. To further investigate the importance of the genetic 
background in determining the occurrence of different 
rearrangements in distinct geographic and/or ethnic 
groups, the normal IGHV repertoire of healthy subjects 
of the same ethnicity and from the same geographic areas 
should also be investigated. Although some evidences are 
reported for Italians [40], at present no data on the normal 
repertoire are available for Chinese population.
In conclusion, the results hereby described offer the 
most extensive catalogue of the BCR features of Chinese 
CLL, being based on the largest series of Chinese CLL 
so far reported. In comparison to Italian CLL, most of 
the Chinese IGHV genes show different frequencies, 
but maintain the same propensity towards mutations and 
stereotypy, with the same clinical impact. The distinctive 
molecular features of IGHV3-21 and IGHV3-23 Chinese 
CLL genes deserve further investigation.
MATERIALS AND METHODS
Patients
A series of 623 patients diagnosed with CLL 
from 3 different institutions situated in China - Nanjing 
(338 cases) and Tianjin (166 cases) - and Hong Kong 
(119 cases), were included in the study. A comparison 
of the three CLL groups, all of Han Chinese ethnicity, 
showed a high degree of internal similarities with 
regard to the somatic hypermutation status and IGHVDJ 
rearrangements. Therefore, the whole cohort of Chinese 
CLL was compared to an Italian cohort of 789 CLL 
patients collected between 2001 and 2014 at the 
Hematology Institute of the “Sapienza” University of 
Rome. The Italian CLL cohort was comparable to the 
Mediterranean series [29,30], and to those reported by 
Agathangelidis et al [28] (Supplementary Table S1).
All satisfied the morphologic and immunophenotypic 
diagnostic criteria for CLL [41]. The characteristics of the 
Chinese and Italian patients are summarized in Table 1. 
Chinese CLL appear older than Italians (p<0.001) and 
in more advanced stages (more stage C) (p= 0.0194). 
Regarding FISH lesions, they show less 11q- (p= 0.0082) 
and 13q-only (p= 0.0026), more trisomy12 (p= 0.0273) 
and more 17p- (p= 0.0457) than Italian CLL. This is in 
contrast with the disease phase at study, which included 
more pre-treated patients in the Italian series. After 
excluding pre-treated patients from both cohorts, we 
confirm all the above mentioned differences (age: p= 
0.0001; stage C: p= 0.0001; 11q-: p= 0.012; 13q only: p= 
0.028; 17p-: p= 0.0108), with the exception of trisomy 12 
(p= 0.3). No difference was observed in the WBC count: 
27.5 x 10^9/L (range 2.1-452.8 x 10^9/L) in Chinese CLL 
and 30.3 x 10^9/L (range 1.7-622.9 x 10^9/L) in Italian 
CLL (p= 0.52).
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Analysis of immunoglobulin rearrangements and 
sequence analysis
In all cases, the analysis of IGHVDJ genes was 
carried out on leukemic cells obtained from peripheral 
blood samples after isolation by Ficoll gradient or 
buffy-coat. PCR amplification and sequence analysis 
of IGHVDJ rearrangements were performed on either 
genomic DNA (gDNA) or cDNA using sense family-
specific VH primers (framework region 1 [FR1] or VH 
leader primers), combined with consensus JH primers as 
previously described [42] or following the IGH Somatic 
Hypermutation Assay v2.0 protocol (InVivoScribe) 
[24]. PCR products were sequenced directly or after a 
cloning procedure, using 3130 Genetic Analyzer (Life 
Technologies, Carlsbad, CA).
Productive rearrangements were analyzed by 
IMGT database (http://imgt.cines.fr, Montepellier, 
France) [43] and the IMGT/V-QUEST tool (version 
3.3.0) [44].
The following features were evaluated for all 
IGHVDJ rearrangements: IGHV gene and allele usage, 
percentage of identity to the closest germline IGHV allele, 
HCDR3 length and composition calculated between codons 
107 and 117, and IGHD-IGHJ gene usage.
To identify clusters of sequences with common 
HCDR3 motifs, we evaluated the HCDR3 region by the 
multiple sequence alignment ClustalW2 software (http://
www.ebi.ac.uk), followed by a manual curation. Clustering 
was performed comparing our HCDR3 sequences to those 
present in literature’s databases [28, 45, 36].
To identify subsets of similar HCDR3, we used 
several criteria. First, for major subsets we followed the 
criteria proposed by Agathangelidis et al. [28] : i) sharing 
at least 50% amino acid identity and 70% similarity 
calculated through common sequence patterns; ii) having 










Sex, M/F 412/190* 520/258* 362/171* 387/199*
  Median age, y 
(range) at diagnosis 60 (16-94) 55 (26-87) 60 (16-94) 55 (26-87)
Stage at study N=575 N=546 N=517 N=461
 A 245 (42.6%) 271 (49.6%) 232 251
 B 141 (24.5%) 181 (33.2%) 127 144
 C 187 (32.5%) 94 (17.2%) 156 66
 Richter 2 (0.4%) - 2 -
Disease phase at 
study N=594 N=729 N=536 N=595
 Diagnosis 290 (48.8%) 304 (41.7%) 290 304
 First progression 246 (41.4%) 291 (39.9%) 246 291
  Subsequent 
progression (post-
treatment)
58 (9.8%) 134 (18.4%) - -
FISH N=373 N=628 N=329 N=535
 del17p 45 (12.1%) 51 (8.12%) 38 34
 del11q 38 (10.2%) 102 (16.24%) 31 82
 Tris12 68 (18.2%) 81 (12.9%) 50 68
 del13q only 98 (26.3%) 223 (35.51%) 101 204
 Normal FISH 124 (33.2%) 171 (27.23%) 109 147
IGHV N=611 N=789 N=536 N=595
 Germline 214 402 167 283
 Mutated 397 387 369 312
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identical HCDR3 lengths and identical offsets of shared 
patterns between sequences; and iii) carrying IGHV genes 
of the same clan. Second, we identified homologous 
HCDR3 as those which shared a HCDR3 homology equal 
to or exceeding 60%, regardless of the usage of the IGHV 
gene: groups of 2 CLL cases with homologous HCDR3 
were defined as paired clusters; clusters of 3 or more cases 
were defined as subsets. Known stereotyped HCDR3s 
were defined and named according to published criteria: 
for major subsets by Agathangelidis et al. [28]; for minor 
subsets by Murray et al. [45] and for novel subsets by 
Rossi et al. [36].
Statistical analysis
Characteristics of patients were summarized by 
means of cross-tabulations (categorical variables), 
quantiles (median etc; for ordinal factors) or by means 
of standard positional and variation parameters (mean, 
standard deviation; for continuous variables). Non-
parametric tests were applied, in univariate analysis, 
for comparisons between groups (Chi-Squared and 
Fisher Exact test for difference in terms of categorical 
variables or response rate, Mann-Whitney and Kruskal-
Wallis test for difference in terms of continuous 
variables).
Overall survival was estimated using the Kaplan-
Meier Product Limit estimator. Differences were 
evaluated by means of Log-Rank test after assessment of 
proportionality of hazards.
TFI was estimated using the proper non-parametric 
method; the Gray test was applied for significance tests on 
cumulative incidence curves.
All the analyses were performed using the SAS 
system software (version 9.4); all tests were two-sided, at 
a significance level of 0.05 and confidence intervals were 
calculated at 95% level.
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